Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis, Two Blades Ink TALEN Technology Cross-licensing Deal

NEW YORK (GenomeWeb) – Ag-bio organizations Cellectis Plant Sciences and the Two Blades Foundation announced that they have signed a cross-licensing agreement for their respective TAL effector nuclease gene-editing technologies.

Under the deal, Two Blades has received a license to Cellectis' TALEN technology for non-profit uses, including its efforts to support subsistence farming, as well as certain commercial applications related to its ongoing disease-resistance programs.

Cellectis has received a license to Two Blades' TAL effector code technology related to nucleases for commercial uses in certain undisclosed crop plants. Cellectis has also been granted an option to expand its license to additional crops.

Financial terms of the arrangement were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.